Preparing For The Return Of Public Markets

Biotech investment is in abeyance after an unprecedented twelve-year run, according to Gregg Beloff, managing director of Danforth Advisors. The capital markets will be back and industry must continue to operate while the bear market persists.

Panelists at LSX World Congress 2023
L-R: Gregg Beloff, Houman Ashrafian and Tim Haines • Source: LSX World Congress

During a panel session at the recent LSX World Congress industry spectators discussed the state of biopharma investing and how companies can prepare now for the return of the public markets.

“While the public markets are pretty depressed, we have the great fortune to be in an environment where pharmaceutical companies...

More from Business Strategy

More from In Vivo

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations

 
• By 

Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.